Advertisement
Document › Details
MGI Tech Co., Ltd.. (2/27/20). "Press Release: MGI and Sophia Genetics Partner to Provide Solutions to Interpret Genomic Data". San José, CA.
Organisation | MGI Tech Co., Ltd. | |
Group | BGI (CN) (Group) | |
Organisation 2 | Sophia Genetics S.A. | |
Group | Sophia Genetics (Group) | |
Product | Sophia DDM (Data Driven Medicine) | |
Product 2 | DNBSEQ® technology | |
Person | Jiang, Hui (BGI 202002 COO of MGI) | |
Person 2 | Puylaert, Kevin (Sophia Genetics 202002 VP Business Development) | |
MGI, part of the global genomics leader BGI Group, announced an agreement with SOPHiA GENETICS to provide MGI’s customers access to the SOPHiA Platform for data analysis and interpretation. By combining MGI’s DNBSEQ™ sequencing technology with SOPHiA’s Platform, MGI provides an effective solution for clinical researchers and further drives adoption of MGI’s genetic sequencers.
Under the terms of the non-exclusive agreement, MGI’s customers will have the ability to utilize SOPHiA to convert various assays already validated in the past onto DNBSEQ™ based sequencers. The SOPHiA Platform supports more than 250 genomic applications and over 1,000 healthcare institutions around the world.
“MGI recognizes that analysis and interpretation of MPS data present challenges to researchers and clinicians, so we are excited to offer the bundled solution of our DNBSEQ™ sequencers with the sophisticated SOPHiA Platform. Our DNBSEQ™ and CoolMPS technologies are not only highly accurate, affordable and sensitive, but also very versatile and easy to adapt to any existing library preparation methodologies. This will enable existing MPS users to use MGI DNBSEQ™ sequencers to advance their research and translational genomic goals,” said Dr. Hui Jiang, COO of MGI.
MGI customers will also benefit from the SOPHiA Set-Up Program to start up new assays or transfer their existing assays into DNBSEQ sequencing platforms. The program is designed to support the implementation of MPS-based testing for somatic and germline assays. The Set-Up Program is a robust process that establishes and demonstrates the analytical performance of a genomic application to save time, money and resources that can ultimately be translated to better patient care.
“We are proud that MGI is working with SOPHiA GENETICS to provide their customers with our universal platformto analyze genomic data produced from its sequencers,” said Kevin Puylaert, VP of Business Development at SOPHiA GENETICS. “This further supports essential access to highly accurate data that healthcare institutions require for reliable testing results. This is an additional effort on our mission to continuously democratize Data-Driven Medicine around the world.”
Record changed: 2023-06-05 |
Advertisement
More documents for BGI (CN) (Group)
- [1] Illumina, Inc.. (5/15/19). "Press Release: Illumina Files Patent Infringement Suit against BGI in Denmark". San Diego, CA....
- [2] Illumina, Inc.. (3/29/19). "Press Release: Illumina Files Patent Infringement Suit against BGI in Germany". San Diego, CA....
- [3] Curetis N.V.. (11/23/18). "Press Release: Curetis Announces Financial Results for the First Nine Months of 2018". Amsterdam, Holzgerlingen & San Diego, CA....
- [4] Curetis N.V.. (4/30/18). "Press Release: Curetis Publishes Full-Year 2017 Financial Results and Updated Guidance for 2018". Amsterdam & Holzgerlingen....
- [5] Curetis N.V.. (3/14/18). "Press Release: Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology". Amsterdam, San Diego, CA & Holzgerlingen....
- [6] Esperite N.V.. (1/31/18). "Press Release: Esperite (ESP) and BGI Genomics (BGI) Sign a Strategic Agreement to Offer Whole Genome Sequencing on a Large Scale". Amsterdam....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top